Vaxart to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 04 2019 - 8:00AM
Business Wire
Vaxart, Inc., a clinical-stage biotechnology company developing
oral recombinant vaccines that are administered by tablet rather
than by injection, today announced that Wouter Latour, M.D.,
president and chief executive officer of Vaxart, will present a
company update and overview at the H.C. Wainwright 21st Annual
Global Investment Conference on Tuesday, September 10, 2019, at
12:30 p.m. EST in New York.
A live webcast of the presentation will be available in the
Investors section of Vaxart’s website at investors.vaxart.com. A
replay of the webcast will be archived on Vaxart’s website for 30
days following the presentation.
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on
developing oral recombinant protein vaccines based on its
proprietary oral vaccine platform. Vaxart’s vaccines are designed
to generate broad and durable immune responses that protect against
a wide range of infectious diseases and may also be useful for the
treatment of chronic viral infections and cancer. Vaxart’s vaccines
are administered using a convenient room temperature-stable tablet,
rather than by injection. Vaxart believes that tablet vaccines are
easier to distribute and administer than injectable vaccines and
have the potential to significantly increase vaccination rates.
Vaxart’s development programs include oral tablet vaccines that are
designed to protect against norovirus, seasonal influenza and
respiratory syncytial virus (RSV), as well as a therapeutic vaccine
for human papillomavirus (HPV). For more information, please visit
www.vaxart.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190904005100/en/
Daniella Funaro Stern Investor Relations 212-362-1200
vaxart@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024